Current Headlines

  1. Vertex Submits Supplemental New Drug Application (sNDA) To U.S. Food And Drug Administration For Use Of KALYDECO (ivacaftor) In People 18 And Older With Cystic Fibrosis Who Have The R117H Mutation
    6/30/2014

    Vertex Pharmaceuticals Incorporated recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of KALYDECO in people with cystic fibrosis (CF) ages 18 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene

  2. CHMP Recommends EU Approval Of VIZAMYL (Flutemetamol F18 Injection) For PET Imaging Of Beta Amyloid Plaque
    6/30/2014

    GE Healthcare recently announced the receipt of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)

  3. Agenus Vaccine Shows Significant Reduction In Viral Burden After HerpV Generated Immune Activation
    6/26/2014

    Agenus Inc. an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, recently announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 (HSV-2)

  4. Leading Foundations Publish Recommendations To Accelerate Drug Repurposing For Neurodegenerative Diseases
    6/26/2014

    A new peer-reviewed publication from the Alzheimer's Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of U.S. Food and Drug Administration (FDA)-approved drugs for the treatment of neurodegenerative diseases

  5. Cook Pharmica, LLC And Selexis SA Establish Customized Biologic Drug Development And Manufacturing Services Platform
    6/24/2014

    Cook Pharmica, LLC, a leading biopharmaceutical contract development and manufacturing organization (CDMO), and Selexis SA, a serial innovation company focused on biologic drug discovery and mammalian cell line development, have built a platform program to offer biopharmaceutical clients an integrated development and manufacturing solution for biologic drugs

  6. PerkinElmer Launches New Innovative Multimode Plate Reader
    6/23/2014

    PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, recently announced the launch of the new EnSight Multimode Plate Reader. The EnSight system is the first plate reader on the market to offer both labeled and label-free detection, together wit well-imaging technology (which facilitates cell imaging), on a single benchtop system

  7. Launch Of Novel, High Throughput PCT-Based Barozyme HT48 System ‘Very Successful’ Says Pressure BioSciences
    6/23/2014

    On June 12, 2014, Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") announced the planned launch of their much anticipated, high throughput pressure cycling technology ("PCT")-based system at the 62nd conference of the American Society for Mass Spectrometry ("ASMS")

  8. Euroscreen To Present ESN364; An Innovative Drug Candidate For The Treatment Of Women’s Health Disorders At The ICE/ENDO Meeting
    6/20/2014

    Euroscreen, a private drug development company, announced today that its ESN364 Phase I clinical candidate, will be presented at the ICE/ENDO Meeting on Sunday, June 22nd (Chicago, IL)

  9. Commercial Launch Of ABL's OncoChek Software
    6/16/2014

    Advanced Biological Laboratories (ABL), S.A., announces the signing of a licensing and collaboration agreement with Tute Genomics. ABL is also pleased to announce the commercial launch of OncoChek for managing and analysing genomics data in the field of oncology

  10. AB SCIEX Launches Innovative Solutions For Therapeutics Development And Analysis
    6/16/2014

    AB SCIEX, a global leader in life science analytical technologies, recently introduced its latest additions to a growing line of solutions for the characterization of biotherapeutics such as monoclonal antibodies and emerging protein classes at both the intact protein and peptide levels

Newsletter Signup
Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers